drugset / Trial / NCT05264038
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
RandomizedSequentialDouble-blindTreatment
Summary
Oncocross is developing OC514, a drug-drug combination product containing 2 active pharmaceutical ingredients for cancer cachexia. This study is designed to assess the safety and tolerability of single and multiple oral doses of OC514 in healthy adult volunteers.
Timeline
- Start
- 2022-03-03
- Primary completion
- 2022-09-07
- Completion
- 2023-03-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OC514 | Unknown | — | Oral |
Indications
No indication recorded.